GAA
CRSP icon

Green Alpha Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Green Alpha Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.14M Buy
56,786
+982
+2% +$53K 2.13% 12
2026
Q2 		$3.04M Sell
55,804
-1,218
-2% -$64.2K 2.04% 11
2026
Q1 		$2.71M Buy
57,022
+1,285
+2% +$67.8K 2.67% 9
2025
Q4 		$2.92M Buy
55,737
+725
+1% +$43.4K 2.68% 7
2025
Q3 		$3.57M Sell
55,012
-3,451
-6% -$198K 3.44% 6
2025
Q2 		$2.84M Buy
58,463
+1,102
+2% +$42.6K 2.72% 9
2025
Q1 		$1.95M Buy
57,361
+32,732
+133% +$1.39M 2.08% 10
2024
Q4 		$969K Buy
24,629
+5,471
+29% +$258K 0.78% 46
2024
Q3 		$900K Sell
19,158
-479
-2% -$24.3K 0.71% 50
2024
Q2 		$1.06M Sell
19,637
-7,319
-27% -$423K 0.85% 40
2024
Q1 		$1.84M Buy
26,956
+2,406
+10% +$172K 1.33% 21
2023
Q4 		$1.54M Sell
24,550
-10,330
-30% -$571K 1.11% 23
2023
Q3 		$1.58M Buy
34,880
+507
+1% +$26.2K 1.22% 21
2023
Q2 		$1.93M Buy
34,373
+1,790
+5% +$102K 1.27% 17
2023
Q1 		$1.47M Buy
32,583
+1,937
+6% +$94.1K 1.03% 31
2022
Q4 		$1.25M Buy
30,646
+3,180
+12% +$169K 1.04% 29
2022
Q3 		$1.79M Sell
27,466
-200,820
-88% -$14.6M 1.52% 7
2022
Q2 		$13.9M Buy
228,286
+202,753
+794% +$11.9M 3.19% 6
2022
Q1 		$1.6M Buy
25,533
+8,374
+49% +$526K 1.08% 30
2021
Q4 		$1.3M Buy
17,159
+2,237
+15% +$195K 0.88% 47
2021
Q3 		$1.67M Buy
14,922
+2,214
+17% +$278K 1.15% 24
2021
Q2 		$2.06M Buy
12,708
+5,914
+87% +$719K 1.4% 7
2021
Q1 		$828K Buy
6,794
+442
+7% +$66.7K 0.82% 51
2020
Q4 		$973K Buy
+6,352
New +$751K 1.18% 27

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
HPBT
Hickory Point Bank & Trust Decatur, Illinois $166M AUM 19.36% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Green Alpha Advisors's CRSP Position: Q3 2026 in Review

Green Alpha Advisors increased its CRISPR Therapeutics (CRSP) stake by 1.8% in Q3 2026, buying an estimated $53K and bringing the position to 56,786 shares worth $3.14M. The position accounts for 2.13% of the portfolio, ranked #12.

Green Alpha Advisors first reported a position in CRSP in Q4 2020 and has held it in 24 quarters since. The position peaked at $13.9M in Q2 2022. 13 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Green Alpha Advisors held 56,786 shares of CRISPR Therapeutics worth $3.14M as of Q3 2026.
  • Green Alpha Advisors bought 982 CRISPR Therapeutics shares in Q3 2026, an estimated $53K.
  • CRISPR Therapeutics made up 2.13% of Green Alpha Advisors's portfolio in Q3 2026, its #12 holding.
  • Green Alpha Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 24 quarters since.
  • Green Alpha Advisors's CRISPR Therapeutics position peaked at $13.9M in Q2 2022.
  • 13 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Green Alpha Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.